Company Overview and News

0
Tabcorp Holdings Limited (TABCF) CEO David Attenborough on Q4 2018 Results - Earnings Call Transcript

2018-08-11 seekingalpha
Tabcorp Holdings Limited (NYSE:CHD) Q4 2018 Results Earnings Conference Call August 7, 2018 8:00 PM ET
GJV TABCF TAH NWS NWSA CHD TACBY

10
Deals of the day-Mergers and acquisitions

2018-07-19 reuters
July 19 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Thursday:
TABCF BABA TAH WKSGY 3407 TACBY

135
As World Cup kicks off, here's how investors can seek to cash in

2018-06-13 malaymail
LONDON, June 14 — The stage has long been set for football’s Fifa World Cup that kicks off in Russia later today. Investors and analysts have already factored in the potential benefits for the likes of brewers, retailers and advertisers. So what opportunities remain?
GNK DB TAH JDSPY CCV ADDYY CCZ WIMHY GMVHF F03 NKE TWTR CMCSK AKAM WIMHF FOX EA ADDDF WYNN JD CMCSA WMH TABCF BKNG CCV.CL FOXA TACBY

9
Australia's Strong Q1 Growth: ETFs in Focus

2018-06-11 zacks
The Australian economy remained strong in the first quarter of 2018 with GDP growth of 3.1% compared to 2.4% in the last quarter of 2017. The reported growth was above expectations of 2.8% expansion and marked the quickest annual growth rate since second-quarter 2016.
MQBKY WBC BSL TAH CHJHF CHA WEBNF MCQEF WBK WHC TABCF WBC BLSFY BLSFF 0728 MQG TACBY

38
Will Slow GDP Growth Take a Beating on Australia ETFs?

2018-03-12 zacks
Australia’s GDP grew slower than expected by economists, as bad weather led to a fall in exports. Construction activity further dragged down the GDP growth, weighing on gains provided by strong household activity.
WBC BLT TAH WLK BHPBF CBAUF NAB NASXF WEBNF NABZY WBK CMWAY NAUBF TABCF WBC BHP CBAUY BBL BHP HVN BHPLF HNORY TACBY

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...